Results 71 to 80 of about 16,400 (167)
Australasian chronic lymphocytic leukaemia consensus statement: 2026 update
Internal Medicine Journal, EarlyView.Abstract In 2023, a consensus statement on the diagnosis and management of chronic lymphocytic leukaemia (CLL) in Australasia was published. Since then, advances in clinical evidence and increased availability of molecular diagnostics and targeted therapies have further influenced contemporary CLL management.
Sean McKeague +27 more
wiley +1 more source
American Journal of Hematology, Volume 101, Issue 9, Page 2280-2287, September 2026.ABSTRACT Despite significant progress in chronic GVHD therapies, challenges remain in understanding pleomorphic phenotypes and varying responses to treatment. The aim of this study was to identify predictors of treatment response. We conducted a prospective, observational cohort study of patients beginning first‐, second‐, or third‐line systemic ...
Betty K. Hamilton +11 more
wiley +1 more source
Blood Neoplasia: Hypertension is a common side effect of Bruton tyrosine kinase inhibitors (BTKis). The second-generation BTKi zanubrutinib has high BTK selectivity, which may minimize off-target effects.
June-Wha Rhee +6 more
doaj +1 more source
A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer
Cancer Medicine, Volume 15, Issue 8, August 2026.ABSTRACT Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2‐positive metastatic breast cancer (MBC) whose disease had progressed on ado‐trastuzumab emtansine ...
Joyce O'Shaughnessy +10 more
wiley +1 more source
Generalized Analysis of Electrophilic Small Molecules
Angewandte Chemie, Volume 138, Issue 28, 6 July 2026.Generalized fragmentation patterns stand to unlock the utility of tandem‐mass spectrometry for chemical reaction analysis but are bottlenecked by time consuming method development. Here were show how we can analyze most electrophilic small molecules the same way by their conjugation with a simple MS/MS encoded chemical probe.
Uma Neelakantan +9 more
wiley +2 more sources
Cancer Medicine, Volume 15, Issue 8, August 2026.ABSTRACT Background Bruton tyrosine kinase inhibitors are central to the treatment of relapsed or refractory mantle cell lymphoma, but cardiovascular and bleeding toxicities influence treatment selection. Ibrutinib has been associated with atrial fibrillation/flutter and other cardiovascular adverse events, whereas second‐generation covalent BTK ...
Anna Homeniuk +3 more
wiley +1 more source
Acute and Chronic Leukemia in Sub‐Saharan Africa: A Systematic Review
Cancer Reports, Volume 9, Issue 8, August 2026.ABSTRACT Background The four primary subgroups of leukemia include chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Very little is known about the regional variation of leukemia and subtypes in sub‐Saharan Africa (SSA).
Allwell A. Ayirebi +17 more
wiley +1 more source
Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real‐World Case Series
eJHaem, Volume 7, Issue 4, August 2026.ABSTRACT Background Relapsed or refractory mantle cell lymphoma (r/r MCL) remains difficult to treat despite therapeutic advances. Methods This multicenter retrospective study included 10 patients with r/r MCL treated with glofitamab across five sites in Austria and Italy before European approval (January 2023–May 2024).
Natalia Rotter +16 more
wiley +1 more source
eJHaem, Volume 7, Issue 4, August 2026.ABSTRACT Cutaneous manifestations of chronic lymphocytic leukemia (CLL) are heterogeneous and may result from leukemic infiltration, secondary malignancies, infectious complications, or reactive inflammatory processes. Reactive angioendotheliomatosis (RAE) is a rare vascular proliferation that has only infrequently been reported in association with ...
Feras Alfraih +4 more
wiley +1 more source